Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Orion Corporation: Decisions by the AGM on 25 March 2014 |
| 25 Mar 2014 |
| Orion Corporation: Organising meeting of the Board of Directors | 25 Mar 2014 |
| Orion Group Financial Statement documents 2013 and Corporate Governance Statement published | 3 Mar 2014 |
| Orion Oyj : Transfer of 119,326 own B-shares on 3 March 2014 | 3 Mar 2014 |
| Orion Group Financial Statement Release for 2013 | 4 Feb 2014 |